Can engineered nanoparticles treat wet age-related macular degeneration?

Written by The Nanomed Zone, Kate Lovesey (Future Science Group)

Researchers at Johns Hopkins University (MD, USA) described in Science Advances the development of a new nanoparticle-delivered gene therapy that could help treat wet age-related macular degeneration and potentially improve patient compliance as well as reduce strain on caregivers. Wet age-related macular degeneration is an inherited disease characterized by abnormal blood vessel growth that damages the light-sensitive tissue in the back of the eye. Currently, there are an estimated 1.6 million people in the USA suffering with wet age-related macular degeneration. Peter Campochiaro (Johns Hopkins University) commented: “Some of the most prevalent inherited retinal degenerations are due to mutations in...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!